Multi‐functional tyrosinase inhibitors derived from kojic acid and hydroquinone‐like diphenols for treatment of hyperpigmentation: Synthesis and in vitro biological evaluation
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Morteza Ashooriha und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, …. Hauptthemen laut MEDLINE: Monophenol Monooxygenase, Pyrones, Hyperpigmentation, Enzyme Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Mazandaran University of Medical Sciences.
Abstract (Originalsprache)
A series of multi‐functional tyrosinase inhibitors derived from kojic acid (KA) and hydroquinone‐like diphenols were designed and synthesized using click chemistry. The in vitro enzymatic assay revealed that all compounds containing a free enolic structure showed excellent activity against tyrosinase (IC 50 = 0.14–3.7 µM), being significantly more potent than KA. The most active compounds were catechol ( 6c ) and α‐naphthol ( 6i ) analogs with 138‐ and 96‐fold higher potency than KA. On the other hand, all free phenolic compounds ( 6a‐c and 6g‐j ) derived from aromatic diols showed outstanding free radical scavenging activities superior to KA. Certainly, the α‐naphthol derivative 6i with IC 50 = 10.1 µM was the most active anti‐oxidant, being as potent as quercetin. The SAR analysis indicated that the enolic head of the conjugate molecules mainly contributes to the anti‐tyrosinase activity, and the free phenolic part of the molecules can offer anti‐oxidant potency. The anti‐melanogenic assay of the most promising derivative, 6i , against melanoma (B16F10) cells demonstrated that the prototype compound 6i can significantly reduce the melanin content, more effectively than KA. By using a conjugation strategy, we have improved the tyrosinase inhibitory and radical scavenging activity in the multi‐functional agents such as 6i over the parent compound KA, being potentially useful in the treatment of hyperpigmentation and other skin disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
- Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York City, New York, USA.
- Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Förderung
- Mazandaran University of Medical Sciences
Zitieren
APA
Ashooriha, M., Khoshneviszadeh, M., Kabiri, M., Dehshahri, A., Hassani, B., Ansari, M., & Emami, S. (2024). Multi‐functional tyrosinase inhibitors derived from kojic acid and hydroquinone‐like diphenols for treatment of hyperpigmentation: Synthesis and in vitro biological evaluation. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400380
Vancouver
Ashooriha M, Khoshneviszadeh M, Kabiri M, Dehshahri A, Hassani B, Ansari M, et al. Multi‐functional tyrosinase inhibitors derived from kojic acid and hydroquinone‐like diphenols for treatment of hyperpigmentation: Synthesis and in vitro biological evaluation. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400380
BibTeX
@article{Ashooriha2024,
author = {Ashooriha, Morteza and Khoshneviszadeh, Mehdi and Kabiri, Maryam and Dehshahri, Ali and Hassani, Bahareh and Ansari, Mahsa and Emami, Saeed},
title = {Multi‐functional tyrosinase inhibitors derived from kojic acid and hydroquinone‐like diphenols for treatment of hyperpigmentation: Synthesis and in vitro biological evaluation},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400380}
}
EUVIMED